BiomX Past Earnings Performance
Past criteria checks 0/6
BiomX has been growing earnings at an average annual rate of 0.6%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
0.6%
Earnings growth rate
46.2%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | -23.0% |
Net Margin | n/a |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How BiomX makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 0 | -9 | 12 | 20 |
30 Jun 24 | 0 | -26 | 10 | 18 |
31 Mar 24 | 0 | -34 | 10 | 15 |
31 Dec 23 | 0 | -26 | 10 | 16 |
30 Sep 23 | 0 | -27 | 9 | 16 |
30 Jun 23 | 0 | -25 | 10 | 14 |
31 Mar 23 | 0 | -27 | 10 | 15 |
31 Dec 22 | 0 | -28 | 11 | 15 |
30 Sep 22 | 0 | -33 | 11 | 19 |
30 Jun 22 | 0 | -36 | 12 | 22 |
31 Mar 22 | 0 | -36 | 12 | 21 |
31 Dec 21 | 0 | -36 | 12 | 22 |
30 Sep 21 | 0 | -35 | 12 | 22 |
30 Jun 21 | 0 | -34 | 11 | 21 |
31 Mar 21 | 0 | -33 | 10 | 21 |
31 Dec 20 | 0 | -30 | 10 | 19 |
30 Sep 20 | 0 | -27 | 11 | 18 |
30 Jun 20 | 0 | -23 | 11 | 15 |
31 Mar 20 | 0 | -22 | 10 | 14 |
31 Dec 19 | 0 | -21 | 9 | 13 |
30 Sep 19 | 0 | -22 | 5 | 11 |
30 Jun 19 | 0 | -19 | 4 | 11 |
31 Mar 19 | 0 | -17 | 4 | 10 |
31 Dec 18 | 0 | -15 | 3 | 9 |
31 Dec 17 | 0 | -7 | 3 | 4 |
Quality Earnings: PHGE is currently unprofitable.
Growing Profit Margin: PHGE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PHGE is unprofitable, but has reduced losses over the past 5 years at a rate of 0.6% per year.
Accelerating Growth: Unable to compare PHGE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PHGE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: PHGE has a negative Return on Equity (-22.97%), as it is currently unprofitable.